Fondaparinux.
Turpie
Alexander G G
AG
Department of Medicine, Hamilton Health Sciences-Hamilton General Hospital and McMaster University, Hamilton, Ontario, Canada.
Eriksson
Bengt I
BI
Bauer
Kenneth A
KA
Lassen
Michael R
MR
D001682:Biological Availability; D017326:Clinical Trials, Phase III as Topic; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D000077425:Fondaparinux; D006622:Hip Prosthesis / Q000009:adverse effects; D006801:Humans; D007720:Knee Prosthesis / Q000009:adverse effects; D008297:Male; D019637:Orthopedic Procedures / Q000009:adverse effects* / Q000379:methods; D011134:Polysaccharides / Q000008:administration & dosage* / Q000191:economics / Q000493:pharmacokinetics; D011183:Postoperative Complications / Q000517:prevention & control; D018570:Risk Assessment; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000517:prevention & control*
D011134:Polysaccharides; D000077425:Fondaparinux